Researcher in a lab coat reviewing a two-peak chromatogram and mass spectrum beside a lyophilized research vial, representing COA verification of a two-component peptide blend
Mindful Research

Sourcing a Two-Component Blend: COA and Ratio Verification (CJC-1295 Ipamorelin 5/5 mg)

By: Mindful Research Team4 min read

Key takeaways

  • A cjc 1295 ipamorelin blend COA must report purity and MS identity for each peptide plus the 5/5 mg ratio.
  • One combined purity number does not tell you the component ratio; ask for per-peptide values.
  • Full vial in 1 mL: ipamorelin 5 mg/mL (7.02 mM), CJC-1295 no DAC 5 mg/mL (1.48 mM), molar ratio about 4.7:1.
  • Confirm the CJC-1295 is the no-DAC form by its formula C152H252N44O42 and mass-spec envelope near 843.0 and 1123.6.
  • For in vitro research use only.

A cjc 1295 ipamorelin blend sourced as a research material should arrive with a Certificate of Analysis that reports each peptide separately: an HPLC purity value for ipamorelin and one for CJC-1295 no DAC, a mass-spectrometry identity for each, and the mass ratio in the vial, which for the catalog product is 5 mg ipamorelin to 5 mg CJC-1295 no DAC. This guide lists what to check on a two-component COA, why a single purity number is not enough, and how to turn the 5/5 mg vial into working stocks expressed in both mg/mL and molarity.

What should a blend COA report?

A single-peptide COA has one identity and one purity line. A blend needs two of each, plus the ratio. The Ipamorelin/CJC-1295 (no DAC) listing states that component identities, ratios and lot-specific purity values are printed on the certificate; the checklist below is what to look for.

COA item Ipamorelin CJC-1295 no DAC
Formula C38H49N9O5 C152H252N44O42
MW (g/mol) 711.9 3367.95
CAS 170851-70-4 863288-34-0
MS signature [M+H]+ about 712.9; [M+2H]2+ about 356.9 [M+4H]4+ about 843.0; [M+3H]3+ about 1123.6
HPLC Separate peak and purity value Separate peak and purity value
Stated mass 5 mg 5 mg

Why is one purity number not enough?

A blend reported as a single "99 percent" figure could mean each peptide is 99 percent pure, or that the two peaks together account for 99 percent of the chromatogram with no information about their ratio. Those are different statements. Ask for the individual purity values and for the area ratio or a gravimetric statement that supports the 5/5 mg claim. If only a combined value is given, the ratio can be estimated from the two HPLC peak areas after correcting for the different extinction coefficients of a 5-residue and a 29-residue peptide at 214 or 220 nm, but a vendor-reported ratio is better. The general approach is in reading a COA line by line and HPLC for peptides: how purity is measured.

How do you confirm both identities?

Two mass spectra, or one spectrum with two clearly assignable species. Ipamorelin at 711.9 g/mol is seen as a singly or doubly charged ion; CJC-1295 no DAC at 3367.95 g/mol appears as a multiply charged envelope. The two cannot be confused, and a DAC-containing CJC-1295 would shift the envelope by about 279 units, as described in CJC-1295 with DAC vs no DAC. See mass spectrometry for peptide identity for how to read the envelope.

Reconstitution math for the 5 mg / 5 mg vial

Reconstituting the entire vial in a given volume of reconstitution solution gives the following stock concentrations for each component simultaneously:

Volume added Ipamorelin CJC-1295 no DAC Molar ratio (Ipa : CJC)
1 mL 5 mg/mL = 7.02 mM 5 mg/mL = 1.48 mM 4.73 : 1
2 mL 2.5 mg/mL = 3.51 mM 2.5 mg/mL = 0.742 mM 4.73 : 1
4 mL 1.25 mg/mL = 1.76 mM 1.25 mg/mL = 0.371 mM 4.73 : 1

The molar ratio is fixed at about 4.7 to 1 whatever the volume, because it is set by the masses in the vial. Working solutions in the nanomolar to micromolar range are made by serial dilution of the stock in assay medium, following peptide concentration and reconstitution math. For an equimolar design, reconstitute the single-component CJC-1295 no DAC and ipamorelin vials separately.

Storage and handling of the blend

Both components are stable as a lyophilized powder when kept cold, dry and dark. After reconstitution, aliquot into single-use volumes and freeze; a 29-residue amphipathic peptide adsorbs to plastic, so low-binding tubes and a carrier-protein-free buffer only for short periods are sensible. Avoid repeated freeze-thaw.

Supplier questions to ask

  • Are purity and identity reported per component?
  • Is the 5/5 mg ratio stated on the COA, and how was it determined?
  • Is the CJC-1295 the no-DAC form (formula C152H252N44O42)?
  • Is an endotoxin value given, if the material will be used in cell culture?

The general supplier checklist is in how to evaluate a research-compound supplier, and the blend's receptor pharmacology in the CJC-1295 + ipamorelin blend profile.

Related research guides

Research-use note

All materials discussed are supplied for in vitro laboratory research use only, and are not for human or animal use.

Frequently asked questions

What should a CJC-1295 ipamorelin blend COA show?

Separate HPLC purity values and mass-spectrometry identities for ipamorelin (711.9 g/mol) and CJC-1295 no DAC (3367.95 g/mol), plus the stated mass ratio, which for the catalog vial is 5 mg to 5 mg. View Ipamorelin/CJC-1295

What concentration does the 5/5 mg vial give in 1 mL?

5 mg/mL of each peptide: 7.02 mM ipamorelin and 1.48 mM CJC-1295 no DAC, a molar ratio of about 4.7 to 1.

Why is the blend not equimolar?

Because the two peptides have very different molecular weights; equal masses give about 4.7 times more moles of the lighter ipamorelin.

How do I know the CJC-1295 is the no-DAC form?

From the formula C152H252N44O42 and a mass-spec envelope near 843.0 (4+) and 1123.6 (3+); a DAC form would be about 279 units heavier. DAC vs no DAC

Is the blend for human or animal use?

No. It is supplied for in vitro laboratory research use only.